Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1980 1
1981 4
1982 13
1983 26
1984 49
1985 81
1986 99
1987 90
1988 124
1989 155
1990 267
1991 271
1992 294
1993 408
1994 371
1995 429
1996 372
1997 351
1998 335
1999 299
2000 305
2001 378
2002 403
2003 454
2004 523
2005 567
2006 616
2007 665
2008 613
2009 650
2010 681
2011 583
2012 347
2013 357
2014 277
2015 241
2016 150
2017 144
2018 118
2019 93
2020 124
2021 82
2022 53
2023 49
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

11,839 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for reaferon
Search for resoferon instead (1 results)
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain.
Burke JR, Cheng L, Gillooly KM, Strnad J, Zupa-Fernandez A, Catlett IM, Zhang Y, Heimrich EM, McIntyre KW, Cunningham MD, Carman JA, Zhou X, Banas D, Chaudhry C, Li S, D'Arienzo C, Chimalakonda A, Yang X, Xie JH, Pang J, Zhao Q, Rose SM, Huang J, Moslin RM, Wrobleski ST, Weinstein DS, Salter-Cid LM. Burke JR, et al. Sci Transl Med. 2019 Jul 24;11(502):eaaw1736. doi: 10.1126/scitranslmed.aaw1736. Sci Transl Med. 2019. PMID: 31341059
Gorham-Stout syndrome.
Liu SZ, Zhou X, Song A, Wang YP, Liu Y. Liu SZ, et al. QJM. 2018 Dec 1;111(12):911-912. doi: 10.1093/qjmed/hcy150. QJM. 2018. PMID: 29986084 No abstract available.
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A. Barbui T, et al. Lancet Haematol. 2021 Mar;8(3):e175-e184. doi: 10.1016/S2352-3026(20)30373-2. Epub 2021 Jan 18. Lancet Haematol. 2021. PMID: 33476571 Clinical Trial.
Adjuvant Therapy of Melanoma.
Davar D, Kirkwood JM. Davar D, et al. Cancer Treat Res. 2016;167:181-208. doi: 10.1007/978-3-319-22539-5_7. Cancer Treat Res. 2016. PMID: 26601863 Free PMC article. Review.
Medical treatment for ocular surface squamous neoplasia.
Monroy D, Serrano A, Galor A, Karp CL. Monroy D, et al. Eye (Lond). 2023 Apr;37(5):885-893. doi: 10.1038/s41433-023-02434-x. Epub 2023 Feb 8. Eye (Lond). 2023. PMID: 36754986 Free PMC article. Review.
Furthermore, technological advancements, such as those seen in high-resolution optical coherence tomography (HR-OCT) for the anterior segment, have facilitated the diagnosis and monitoring of OSSN. When selecting a topical agent, interferon alpha-2b (IFNalpha-2b) and 5-flu …
Furthermore, technological advancements, such as those seen in high-resolution optical coherence tomography (HR-OCT) for the anterior segmen …
Systemic mastocytosis.
Austen KF. Austen KF. N Engl J Med. 1992 Feb 27;326(9):639-40. doi: 10.1056/NEJM199202273260912. N Engl J Med. 1992. PMID: 1734257 Clinical Trial. No abstract available.
Novel treatment strategies for myeloproliferative neoplasms.
Bose P, Masarova L, Verstovsek S. Bose P, et al. Rinsho Ketsueki. 2019;60(9):1176-1185. doi: 10.11406/rinketsu.60.1176. Rinsho Ketsueki. 2019. PMID: 31597841 Review.
Although the Janus kinase (JAK) inhibitor ruxolitinib has long been the only drug licensed for treatment of the classic Philadelphia chromosome negative (Ph(-)) myeloproliferative neoplasms, years of drug development efforts have begun to bear fruit with the recent approval of a …
Although the Janus kinase (JAK) inhibitor ruxolitinib has long been the only drug licensed for treatment of the classic Philadelphia chromos …
[Reaferon in the treatment of hemorrhagic fever with the renal syndrome].
Ivanov KS, Roshchupkin VI, Koshil' OI, Morozov VG, Utkin VN. Ivanov KS, et al. Antibiot Khimioter. 1994 Jan;39(1):42-6. Antibiot Khimioter. 1994. PMID: 8060195 Clinical Trial. Russian.
The use of reaferon in the complex therapy resulted in a decrease in the period of the general intoxication by 3.4 +/- 1.3 days. ...Reaferon promoted a decrease in the concentration of the circulating immune complexes of the blood serum. ...
The use of reaferon in the complex therapy resulted in a decrease in the period of the general intoxication by 3.4 +/- 1.3 days. ... …
Interferons--expanding therapeutic roles.
Borden EC. Borden EC. N Engl J Med. 1992 May 28;326(22):1491-3. doi: 10.1056/NEJM199205283262209. N Engl J Med. 1992. PMID: 1374161 No abstract available.
11,839 results
You have reached the last available page of results. Please see the User Guide for more information.